You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Physiological Role of Bile Acids by Gut Microbiome: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Endocrinology & Metabolism | Biochemistry & Molecular Biology
Contributor: Yoshimitsu Kiiriyama

Bile acids (BAs) are produced from cholesterol in the liver and are termed primary BAs. Primary BAs are conjugated with glycine and taurine in the liver and then released into the intestine via the gallbladder. After the deconjugation of glycine or taurine by the gut microbiome, primary BAs are converted into secondary BAs by the gut microbiome through modifications such as dehydroxylation, oxidation, and epimerization. 

  • bile acids
  • gut microbiota
  • FXR
  • TGR5
  • SHP
  • FGF
  • Hippo
  • Mst1
  • Mst2
  • MRGPRX4
  • isoalloLCA

1. The Role of Modified Bile Acids  in the Metabolic System

The main BA receptors are FXR and TGR5. BA binding to FXR and TGR5 regulates BA, glucose, and lipid levels. CDCA and DCA have a high affinity for FXR [1][2][3][4] and conjugated DCA acts as a ligand for FXR with NTCP—a BA transporter expressed in the cell [1].
FXR regulates the expression of various genes by binding to specific DNA sequences in the genome, either as a monomer or as a heterodimer with the retinoid X receptor (RXR). These specific DNA sequences are an inverted repeat of AGGTCA separated by one nucleotide (IR1), IR0, an everted repeat of AGGTCA separated by two or eight nucleotides (ER2 or 8), and a direct repeat of AGGTCA separated by one, four, or five nucleotides (DR1, 4, or 5) [5][6][7][8][9]. FXR also regulates epigenetic modifications. The activation of FXR recruits steroid receptor coactivator 1 (SRC1), which has histone acetyltransferase (HAT) activity in its C-terminal region, leading to the acetylation of histone H3 at the promoter of the glucagon-like peptide 1 (GLP-1) receptor [10][11][12]. In addition, FXR induces the expression of microRNA-29a, which downregulates DNA methyltransferases [13] and histone deacetylase (HDAC) 4 [14]. It has been shown that the percentage of common DNA binding sites of FXR between the liver and intestine is only 11% [6]. This suggests that the pattern of gene expression regulated by FXR is tissue-specific. Furthermore, FXR induces the expression of TGR5 [15].
TGR5 is a member of the G-protein-coupled receptor (GPCR) superfamily and couples to Gαs. Activated TGR5 leads to the activation of adenylyl cyclase, an increase in cyclic AMP (cAMP) concentration, and the activation of protein kinase A (PKA) and exchange proteins directly activated by cAMP (EPAC) [16]. LCA, DCA, CDCA, CA, and conjugated forms of these BAs activate TGR5. LCA and DCA, which are secondary BAs, and their conjugated forms were reported as the most effective TGR5 activators [17][18][19]. Additionally, UDCA is a weak activator of TGR5 [18][20].

1.1. BA Metabolism

FXR inhibits BA synthesis by inducing small heterodimer partner (SHP), a nuclear receptor that lacks a ligand-binding domain [21]. SHP interacts with and represses nuclear receptors and transcription factors, including PXR, CAR, LXR, GR, and FXR [22][23]. SHP also inhibits the activation of liver receptor homolog-1 (LRH-1), which induces CYP7A1, the key enzyme responsible for BA synthesis from cholesterol [24] (Figure 1A). Furthermore, FXR also inhibits the expression of CYP7A1 by inducing fibroblast growth factor (FGF) 15/19 (mouse FGF15 and human FGF19) and β-Klotho (βKL). βKL forms binary complexes with FGF receptor 4 (FGFR4) to function as a coreceptor of FGFR4 for FGF15/19 [25]. Transcription factor EB (TFEB) is activated by dephosphorylation and induces CYP7A1. After activating FGFR4/βKL by FGF15/19, the mechanistic target of rapamycin phosphorylates and inactivates TFEB, leading to CYP7A1 repression [26]. FGF15/19 also stabilizes SHP, which represses CYP7A1 and CYP8B1. CYP8B1 is a key enzyme for the synthesis of CA. The binding of FGF15 to FGFR4 activates the Hippo signaling pathway. In the Hippo signaling pathway, SHP is phosphorylated and stabilized by mammalian sterile 20-like kinase 1 (Mst1) and Mst2, homologs of the Hippo kinase in Drosophila [27] (Figure 1B). FXR also regulates BA transporters. FXR represses NTCP in the liver, leading to a reduction of the hepatic uptake of Bas [28]. On the other hand, FXR enhances BA efflux into the liver by inducing BSEP and OSTα/β [29][30]. Overall, FXR reduces excess Bas in the liver. Although TGR5 is weakly expressed in the liver, TGR5-knockout mice exhibit a decrease in total BA pool size [31]. Additionally, TGR5-knockout mice exhibit reduced levels of CYP7B1 and increased levels of secondary and hydrophobic Bas [32][33][34]. PXR is activated by LCA [35][36] and PXR regulates the expression of CYP3A and CYP2B, which convert LCA to hyocholic acid (HCA) and UDCA [37][38][39]. In addition, PXR indirectly suppresses the expression of CYP7A1 by inhibiting the activation of hepatocyte nuclear factor 4α, which upregulates the expression of CYP7A1 [40][41]. VDR is also activated by LCA and its metabolite, 3-keto LCA [42][43], and LCA induces the expression of CYP3A [43][44][45]. LXRα is weakly activated by hyodeoxycholic acid (HDCA) [46]. The BA pool size and its excretion are decreased in LXRα-knockout mice. LXRα-knockout mice also exhibit reduced CYP7A expression [47], but LXRβ-knockout mice do not [48].
Microorganisms 10 00068 g002 550
Figure 1. Bile acid metabolism by FXR (A) Farnesoid X receptor (FXR) induces small heterodimer partner (SHP) and SHP inhibits liver receptor homolog-1 (LRH-1), which induces cytochrome P450 (CYP) 7A1 in the hepatocyte. (B) FXR induces fibroblast growth factor (FGF) 15/19 (mouse FGF15 and human FGF19) and FGF15/19 in the enterocytes. In the hepatocyte, FGF15/19 activates FGF receptor 4 (FGFR4) and its coreceptor β-Klotho (βKL), leading to the phosphorylation of transcription factor EB (TFEB) by the mechanistic target of rapamycin (mTOR). TFEB induces CYP7A1 and is inactivated by the phosphorylation. The binding of FGF15 to FGFR4 activates mammalian sterile 20-like kinases 1 (Mst1) and Mst2, homologs of the Hippo kinase in Drosophila. MST1 and 2 phosphorylate and stabilize SHP, which represses CYP7A1 and CYP8B1.

1.2. Glucose Metabolism

Glucose and insulin upregulate and downregulate FXR expression, respectively, and FXR is associated with glucose metabolism [49][50]. The association between FXR and glucose metabolism is differently affected by the fed and fasting states. In the fed state, treatment of wild-type mice with the FXR ligand decreases the expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase). PEPCK and G6Pase are essential for the upregulation of gluconeogenesis. In contrast, treatment of wild-type mice in the fasting state with FXR ligand increases the expression of PEPCK and G6Pase. FXR-knockout mice exhibit decreased blood glucose levels, and PEPCK and G6Pase expression are downregulated. The effects of FXR with the FXR ligand are mediated by GR [51]. The treatment of wild-type mice with CA reduces blood glucose levels and PEPCK and GP6ase expression. Furthermore, the treatment of SHP-knockout mice with CA increases blood glucose levels. Thus, the blood glucose-lowering effect of FXR is, at least in part, mediated by SHP [52]. FXR also inhibits PEPCK and G6Pase expression by inducing FGF15/19. FGF15/19 inactivates the cAMP regulatory element-binding protein (CREB), the transcription factor that induces peroxisome proliferator-activated receptor (PPAR)-γ coactivator-1α (PGC-1α) [53]. PGC-1α is a coactivator that induces the expression of genes involved in metabolic pathways and mitochondria by interacting with a variety of nuclear receptors [54][55]. FXR interacts with the carbohydrate responsive element binding protein (ChREBP) and suppresses the activity of ChREBP. ChREBP is a transcription factor that regulates the expression of genes controlling glycolysis and lipogenesis. ChREBP upregulates the expression of L-pyruvate kinase (L-PK), a key enzyme for glycolysis [56]. Activated FXR releases ChREBP and its coactivators (p300 and CREB-binding protein) from the L-PK promoter region and inhibits L-PK expression [57]. FXR and CDCA induce glucose transporter 4 expression in differentiated 3T3-L1 adipocytes and the hepatic cell line HepG2 [58]. FXR increases glucose-stimulated insulin secretion and expression by inducing the KLF11 transcription factor [50]. Although CDCA increases the glucose-stimulated secretion of insulin from wild-type mice, FXR-knockout mice are unaffected [59].
TGR5 activation increases the intestinal level of GLP-1 [60][61][62][63][64]. LCA, taurodeoxycholic acid (TDCA), and TLCA increases GLP-1 secretion via TGR5 activation [60][62]. GLP-1 release is mediated by TGR5 located in the basolateral membrane of L-cells [62]. Most active GLP-1 is degraded in the intestine and liver and 10–15% of secreted GLP-1 from the intestine reaches the pancreas via the systemic circulation [65]. GLP-1 induces the release and synthesis of insulin in β-cells in the pancreatic islets. The binding of GLP-1 to GLP-1 receptor activates adenylate cyclase, leading to increased cAMP levels. PKA and EPAC are then activated, which induces an increase in intracellular Ca2+ from the ER and extracellular sources via voltage-dependent Ca2+ channels [65][66]. Additionally, the activation of PKA by GLP-1 leads to the activation of pancreatic duodenal homeobox-1 protein (PDX-1), which binds to the promoter of the gene encoding insulin and induces the synthesis of insulin [65][67] (Figure 2). In contrast to TGR5, FXR suppresses GLP-1 production in L-cells by inhibiting the activity of ChREBP, which induces the expression and secretion of GLP-1 in L-cells [57][68]. Furthermore, the level of serum HCA is lower in diabetics and people with a high body mass index [69][70][71]. HCA induces GLP-1 by activating TGR5 and inhibiting FXR, and TGR5 activation increases serum insulin and decreases blood glucose levels [69].
Microorganisms 10 00068 g003 550
Figure 2. The regulation of insulin secretion and synthesis via TGR5 and FXR. TGR5 located in the basolateral membrane of L-cells mediates glucagon-like peptide 1 (GLP-1) secretion from L-cells, and secreted GLP-1 from the intestine reaches pancreatic β-cells via the systemic circulation. The binding of GLP-1 to GLP-1 receptor (GLP1R) increases cyclic AMP (cAMP) levels, leading to the activation of protein kinase A (PKA) and exchange proteins directly activated by cAMP (EPAC), which induces an increase in intracellular Ca2+ and insulin secretion. In addition, the activation of PKA by GLP-1 leads to the activation of pancreatic duodenal homeobox-1 protein (PDX-1), which binds to the promoter of the gene encoding insulin and induces the synthesis of insulin. FXR suppresses GLP-1 production in L-cells by inhibiting the activity of a carbohydrate responsive element binding protein (ChREBP) that induces the expression and secretion of GLP-1 in L-cells.

1.3. Lipid Metabolism

Dietary lipids (triglycerides [TGs], cholesterol, and phospholipids) are absorbed and incorporated into chylomicrons in the intestine. Chylomicrons are then converted to very low-density lipoprotein (VLDL) in the liver. VLDL transports lipids from the liver to the systemic circulation. VLDL is then converted to HDL and returned to the liver [72]. In the process of lipogenesis, acetyl-CoA carboxylase (ACC) converts acetyl-CoA to malonyl-CoA, and fatty acid synthase (FAS) converts malonyl-CoA to palmitate. Stearoyl-CoA desaturase (SCD) mediates the conversion of saturated fatty acids (FAs) to monounsaturated FAs, and the newly-produced FAs are then stored as TGs. Sterol regulatory element-binding protein 1C (SREBP1C) is a transcription factor that induces lipogenic genes, including FAS, ACC, and SCD [73][74]. FXR-knockout mice exhibit an increase in SREBP1C, SCD-1, and FAS and also exhibit increased levels of serum and liver TGs, serum cholesterols, and serum free FAs (FFAs) [52]. Additionally, CA feeding decreases the serum levels of TGs, cholesterol, and FFAs in mice [52][75]. CA and CDCA decrease the expression of FAS, ACC, SCD, and SREBP1C [75]. SHP induced by FXR suppresses lipogenesis by suppressing lipogenic genes via the inhibition of LXR, which induces SREBP1C expression [75][76]. Furthermore, FXR induces the expression of carboxylesterase 1 (CES1), which reduces hepatic TGs by inducing TG hydrolysis to release FFAs. Released FFAs activate PPARα, leading to the enhancement of FA oxidation [77][78].

2. Role of Modified BAs in the Immune System

The liver in FXR-knockout mice exhibits an elevated expression of pro-inflammatory genes, such as interleukin-1 (IL-1), IL-6, interferon-γ (IFN-γ), inducible nitric oxide synthase, and cyclooxygenase-2. FXR activation inhibits the expression of these genes by inhibiting the activity of nuclear factor-κB (NF-κB), and also has an anti-inflammatory function [79]. Moreover, CDCA inhibits the production of IL-1, IL-6, and tumor necrosis factor α (TNFα) by human monocytes [80]. FXR activation by agonists leads to conjugation with small ubiquitin-like modifier (SUMO) 2. SUMOylated FXR interacts with NF-κB and nuclear receptor corepressor (NCOR) 1 or NCOR2, also called silencing mediator of retinoic acid and thyroid hormone receptor. NCORs are transcriptional corepressors that repress pro-inflammatory gene expression in the liver [81][82][83][84]. FXR also upregulates SHP. SHP overexpression inhibits NF-κB activation and leads to the downregulation of pro-inflammatory genes in the liver. In contrast, SHP deletion activates NF-κB. Thus, FXR can suppress NF-κB activation by inducing SHP [85]. The inhibitory effect of SHP on NF-κB is mediated by the binding of SHP to NF-κB [86].
Macrophages express both FXR and TGR5. Macrophages from FXR-knockout mice exhibit enhanced release of pro-inflammatory cytokines [84]. CDCA and FXR agonists reduce IL-6 expression in macrophages. However, IL-6 expression is unaffected by FXR agonists in FXR-knockout mice [87]. Activation of TGR5 leads to the suppression of pro-inflammatory cytokines from LSP-stimulated macrophages [88]. The activation of macrophage TGR5 by INT-777, a TGR5 agonist, inhibits pro-inflammatory cytokine production. This inhibition is mediated by cAMP signaling, followed by NF-κB inhibition [88]. Furthermore, TGR5 activation promotes macrophage polarization from M1 (pro-inflammatory phenotype) to M2 (anti-inflammatory phenotype) macrophages and reduces pro-inflammatory cytokines [89][90][91]. In contrast, macrophage differentiation is unaffected by FXR-knockout [87].
Dendritic cells are antigen-presenting cells that play an essential role in the adaptive immune system and express TGR5. DCA suppresses lipopolysaccharide (LPS)-induced expression of pro-inflammatory genes, including IL-1, IL-6, and TNFα in dendritic cells. Furthermore, TGR5-knockout mice exhibit a recovery of LPS-induced expression of pro-inflammatory genes. These inhibitory effects of TGR5 are mediated by the repression of NF-κB via TGR5–cAMP–PKA signaling [92].
Recent studies have shown that 3-oxoLCA and isoalloLCA regulate T cell differentiation. IsoalloLCA triggers oxidative phosphorylation in mitochondria, leading to the production of reactive oxygen species (ROS). ROS from the mitochondria, not from the cytoplasm, induces forkhead box P3 (FOXP3). FOXP3 is a transcription factor and a master regulator of the development of regulatory T cells (Tregs), which release immunosuppressive factors. This 3-oxoLCA acts as an inverse agonist of retinoid-related orphan receptor γt (RORγt), leading to the inhibition of the development of T helper 17 (Th17) cells, which release pro-inflammatory factors. Both 3-oxoLCA and isoalloLCA are not produced in germ-free mice [93][94]. It has been reported that Odoribacteraceae strains can produce isoalloLCA via 5α-reductase and 3β-HSDH. Moreover, isoalloLCA shows selective antibacterial activity against gram-positive multidrug-resistant pathogens [95].

This entry is adapted from the peer-reviewed paper 10.3390/microorganisms10010068

References

  1. Wang, H.; Chen, J.; Hollister, K.; Sowers, L.C.; Forman, B.M. Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR. Mol. Cell 1999, 3, 543–553.
  2. Makishima, M.; Okamoto, A.Y.; Repa, J.J.; Tu, H.; Learned, R.M.; Luk, A.; Hull, M.V.; Lustig, K.D.; Mangelsdorf, D.J.; Shan, B. Identification of a Nuclear Receptor for Bile Acids. Science 1999, 284, 1362–1365.
  3. Parks, D.J.; Blanchard, S.G.; Bledsoe, R.K.; Chandra, G.; Consler, T.G.; Kliewer, S.A.; Stimmel, J.B.; Willson, T.M.; Zavacki, A.M.; Moore, D.D.; et al. Bile Acids: Natural Ligands for an Orphan Nuclear Receptor. Science 1999, 284, 1365–1368.
  4. Distrutti, E.; Santucci, L.; Cipriani, S.; Renga, B.; Schiaroli, E.; Ricci, P.; Donini, A.; Fiorucci, S. Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa. J. Gastroenterol. 2015, 50, 707–719.
  5. Seol, W.; Choi, H.S.; Moore, D.D. Isolation of proteins that interact specifically with the retinoid X receptor: Two novel orphan receptors. Mol. Endocrinol. 1995, 9, 72–85.
  6. Thomas, A.M.; Hart, S.; Kong, B.; Fang, J.; Zhong, X.-B.; Guo, G.L. Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology 2009, 51, 1410–1419.
  7. Laffitte, B.A.; Kast, H.R.; Nguyen, C.M.; Zavacki, A.M.; Moore, D.D.; Edwards, P.A. Identification of the DNA Binding Specificity and Potential Target Genes for the Farnesoid X-activated Receptor. J. Biol. Chem. 2000, 275, 10638–10647.
  8. Kast, H.R.; Goodwin, B.; Tarr, P.T.; Jones, S.A.; Anisfeld, A.M.; Stoltz, C.M.; Tontonoz, P.; Kliewer, S.; Willson, T.M.; Edwards, P.A. Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptor. J. Biol. Chem. 2002, 277, 2908–2915.
  9. Edwards, P.A.; Kast, H.R.; Anisfeld, A.M. BAREing it all: The adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 2002, 43, 2–12.
  10. Xu, J.; Wu, R.-C.; O’Malley, B.W. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat. Rev. Cancer 2009, 9, 615–630.
  11. Kong, X.; Feng, L.; Yan, D.; Li, B.; Yang, Y.; Ma, X. FXR-mediated epigenetic regulation of GLP-1R expression contributes to enhanced incretin effect in diabetes after RYGB. J. Cell. Mol. Med. 2021, 1–12.
  12. Kong, X.; Li, B.; Deng, Y.; Ma, X. FXR Mediates Adenylyl Cyclase 8 Expression in Pancreatic beta-Cells. J. Diabetes Res. 2019, 2019, 8915818.
  13. Yang, Y.-L.; Kuo, H.-C.; Wang, F.-S.; Huang, Y.-H. MicroRNA-29a Disrupts DNMT3b to Ameliorate Diet-Induced Non-Alcoholic Steatohepatitis in Mice. Int. J. Mol. Sci. 2019, 20, 1499.
  14. Huang, Y.-H.; Tiao, M.-M.; Huang, L.-T.; Chuang, J.-H.; Kuo, K.-C.; Yang, Y.-L.; Wang, F.-S. Activation of Mir-29a in Activated Hepatic Stellate Cells Modulates Its Profibrogenic Phenotype through Inhibition of Histone Deacetylases 4. PLoS ONE 2015, 10, e0136453.
  15. Pathak, P.; Liu, H.; Boehme, S.; Xie, C.; Krausz, K.W.; Gonzalez, F.; Chiang, J.Y.L. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. J. Biol. Chem. 2017, 292, 11055–11069.
  16. Kumar, D.P.; Asgharpour, A.; Mirshahi, F.; Park, S.H.; Liu, S.; Imai, Y.; Nadler, J.L.; Grider, J.R.; Murthy, K.S.; Sanyal, A.J. Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis. J. Biol. Chem. 2016, 291, 6626–6640.
  17. Duboc, H.; Taché, Y.; Hofmann, A.F. The bile acid TGR5 membrane receptor: From basic research to clinical application. Dig. Liver Dis. 2014, 46, 302–312.
  18. Kawamata, Y.; Fujii, R.; Hosoya, M.; Harada, M.; Yoshida, H.; Miwa, M.; Fukusumi, S.; Habata, Y.; Itoh, T.; Shintani, Y.; et al. A G Protein-coupled Receptor Responsive to Bile Acids. J. Biol. Chem. 2003, 278, 9435–9440.
  19. Maruyama, T.; Miyamoto, Y.; Nakamura, T.; Tamai, Y.; Okada, H.; Sugiyama, E.; Nakamura, T.; Itadani, H.; Tanaka, K. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 2002, 298, 714–719.
  20. De Marino, S.; Carino, A.; Masullo, D.; Finamore, C.; Marchianò, S.; Cipriani, S.; Di Leva, F.S.; Catalanotti, B.; Novellino, E.; Limongelli, V.; et al. Hyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonists. Sci. Rep. 2017, 7, srep43290.
  21. Huang, C.; Wang, J.; Hu, W.; Wang, C.; Lu, X.; Tong, L.; Wu, F.; Zhang, W. Identification of functional farnesoid X receptors in brain neurons. FEBS Lett. 2016, 590, 3233–3242.
  22. Zhang, Y.; Hagedorn, C.H.; Wang, L. Role of nuclear receptor SHP in metabolism and cancer. Biochim. Biophys. Acta 2011, 1812, 893–908.
  23. Chanda, D.; Park, J.-H.; Choi, H.-S. Molecular Basis of Endocrine Regulation by Orphan Nuclear Receptor Small Heterodimer Partner. Endocr. J. 2008, 55, 253–268.
  24. Goodwin, B.; Jones, S.A.; Price, R.R.; Watson, M.A.; McKee, D.D.; Moore, L.B.; Galardi, C.; Wilson, J.G.; Lewis, M.C.; Roth, M.E.; et al. A Regulatory Cascade of the Nuclear Receptors FXR, SHP-1, and LRH-1 Represses Bile Acid Biosynthesis. Mol. Cell 2000, 6, 517–526.
  25. Fu, T.; Kim, Y.C.; Byun, S.; Kim, D.H.; Seok, S.; Suino-Powell, K.; Xu, H.E.; Kemper, B.; Kemper, J.K. FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of beta-Klotho. Mol. Endocrinol. 2016, 30, 92–103.
  26. Wang, Y.; Gunewardena, S.; Li, F.; Matye, D.J.; Chen, C.; Chao, X.; Jung, T.; Zhang, Y.; Czerwinski, M.; Ni, H.M.; et al. An FGF15/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis. Nat. Commun. 2020, 11, 3612.
  27. Ji, S.; Liu, Q.; Zhang, S.; Chen, Q.; Wang, C.; Zhang, W.; Xiao, C.; Li, Y.; Nian, C.; Li, J.; et al. FGF15 Activates Hippo Signaling to Suppress Bile Acid Metabolism and Liver Tumorigenesis. Dev. Cell 2019, 48, 460–474.e9.
  28. Denson, L.A.; Sturm, E.; Echevarria, W.; Zimmerman, T.L.; Makishima, M.; Mangelsdorf, D.; Karpen, S.J. The Orphan Nuclear Receptor, shp, Mediates Bile Acid-Induced Inhibition of the Rat Bile Acid Transporter, ntcp. Gastroenterology 2001, 121, 140–147.
  29. Zollner, G.; Wagner, M.; Fickert, P.; Geier, A.; Fuchsbichler, A.; Silbert, D.; Gumhold, J.; Zatloukal, K.; Kaser, A.; Tilg, H.; et al. Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. Am. J. Physiol. Liver Physiol. 2005, 289, G798–G805.
  30. Ijssennagger, N.; Janssen, A.W.; Milona, A.; Pittol, J.M.R.; Hollman, D.A.; Mokry, M.; Betzel, B.; Berends, F.; Janssen, I.M.; van Mil, S.W.; et al. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid. J. Hepatol. 2016, 64, 1158–1166.
  31. Maruyama, T.; Tanaka, K.; Suzuki, J.; Miyoshi, H.; Harada, N.; Nakamura, T.; Miyamoto, Y.; Kanatani, A.; Tamai, Y. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J. Endocrinol. 2006, 191, 197–205.
  32. Spatz, M.; Ciocan, D.; Merlen, G.; Rainteau, D.; Humbert, L.; Gomes-Rochette, N.; Hugot, C.; Trainel, N.; Mercier-Nomé, F.; Domenichini, S.; et al. Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis. JHEP Rep. 2021, 3, 100230.
  33. Donepudi, A.C.; Boehme, S.; Li, F.; Chiang, J.Y. G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. Hepatology 2017, 65, 813–827.
  34. Bidault-Jourdainne, V.; Merlen, G.; Glénisson, M.; Doignon, I.; Garcin, I.; Péan, N.; Boisgard, R.; Ursic-Bedoya, J.; Serino, M.; Ullmer, C.; et al. TGR5 controls bile acid composition and gallbladder function to protect the liver from bile acid overload. JHEP Rep. 2021, 3, 100214.
  35. Staudinger, J.L.; Goodwin, B.; Jones, S.A.; Hawkins-Brown, D.; MacKenzie, K.I.; LaTour, A.; Liu, Y.; Klaassen, C.D.; Brown, K.K.; Reinhard, J.; et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. USA 2001, 98, 3369–3374.
  36. Schuster, D.; Langer, T. The Identification of Ligand Features Essential for PXR Activation by Pharmacophore Modeling. J. Chem. Inf. Model. 2005, 45, 431–439.
  37. Kliewer, S.A.; Goodwin, B.; Willson, T.M. The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism. Endocr. Rev. 2002, 23, 687–702.
  38. Xie, W.; Barwick, J.L.; Simon, C.M.; Pierce, A.M.; Safe, S.; Blumberg, B.; Guzelian, P.S.; Evans, R.M. Reciprocal activation of Xenobiotic response genes by nuclear receptors SXR/PXR and CAR. Genes Dev. 2000, 14, 3014–3023.
  39. Willson, T.M.; Kliewer, S.A. Pxr, car and drug metabolism. Nat. Rev. Drug Discov. 2002, 1, 259–266.
  40. Li, T.; Chiang, J. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7α-hydroxylase gene transcription. Am. J. Physiol. Liver Physiol. 2005, 288, G74–G84.
  41. Bhalla, S.; Ozalp, C.; Fang, S.; Xiang, L.; Kemper, J.K. Ligand-activated Pregnane X Receptor Interferes with HNF-4 Signaling by Targeting a Common Coactivator PGC-1α. J. Biol. Chem. 2004, 279, 45139–45147.
  42. Masuno, H.; Ikura, T.; Morizono, D.; Orita, I.; Yamada, S.; Shimizu, M.; Ito, N. Crystal structures of complexes of vitamin D receptor ligand-binding domain with lithocholic acid derivatives. J. Lipid Res. 2013, 54, 2206–2213.
  43. Makishima, M.; Lu, T.T.; Xie, W.; Whitfield, G.K.; Domoto, H.; Evans, R.M.; Haussler, M.R.; Mangelsdorf, D.J. Vitamin D Receptor As an Intestinal Bile Acid Sensor. Science 2002, 296, 1313–1316.
  44. Pavek, P.; Pospechova, K.; Svecova, L.; Syrova, Z.; Stejskalova, L.; Blazkova, J.; Dvorak, Z.; Blahoš, J. Intestinal cell-specific vitamin D receptor (VDR)-mediated transcriptional regulation of CYP3A4 gene. Biochem. Pharmacol. 2010, 79, 277–287.
  45. Matsubara, T.; Yoshinari, K.; Aoyama, K.; Sugawara, M.; Sekiya, Y.; Nagata, K.; Yamazoe, Y. Role of Vitamin D Receptor in the Lithocholic Acid-Mediated CYP3A Induction in Vitro and in Vivo. Drug Metab. Dispos. 2008, 36, 2058–2063.
  46. Song, C.; Hiipakka, R.A.; Liao, S. Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs. Steroids 2000, 65, 423–427.
  47. Peet, D.J.; Turley, S.D.; Ma, W.; Janowski, B.A.; Lobaccaro, J.M.; Hammer, R.E.; Mangelsdorf, D.J. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998, 93, 693–704.
  48. Alberti, S.; Schuster, G.; Parini, P.; Feltkamp, D.; Diczfalusy, U.; Rudling, M.; Angelin, B.; Bjorkhem, I.; Pettersson, S.; Gustafsson, J.A. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J. Clin. Investig. 2001, 107, 565–573.
  49. Duran-Sandoval, D.; Mautino, G.; Martin, G.; Percevault, F.; Barbier, O.; Fruchart, J.-C.; Kuipers, F.; Staels, B. Glucose Regulates the Expression of the Farnesoid X Receptor in Liver. Diabetes 2004, 53, 890–898.
  50. Renga, B.; Mencarelli, A.; Vavassori, P.; Brancaleone, V.; Fiorucci, S. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim. Biophys. Acta 2010, 1802, 363–372.
  51. Renga, B.; Mencarelli, A.; D’Amore, C.; Cipriani, S.; Baldelli, F.; Zampella, A.; Distrutti, E.; Fiorucci, S. Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. FASEB J. 2012, 26, 3021–3031.
  52. Ma, K.; Saha, P.K.; Chan, L.; Moore, D.D. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Investig. 2006, 116, 1102–1109.
  53. Potthoff, M.J.; Boney-Montoya, J.; Choi, M.; He, T.; Sunny, N.E.; Satapati, S.; Suino-Powell, K.; Xu, H.E.; Gerard, R.D.; Finck, B.N.; et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab. 2011, 13, 729–738.
  54. Kiriyama, Y.; Nochi, H. Intra- and Intercellular Quality Control Mechanisms of Mitochondria. Cells 2017, 7, 1.
  55. Rowe, G.C.; Arany, Z. Genetic models of PGC-1 and glucose metabolism and homeostasis. Rev. Endocr. Metab. Disord. 2013, 15, 21–29.
  56. Kawaguchi, T.; Takenoshita, M.; Kabashima, T.; Uyeda, K. Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation/dephosphorylation of the carbohydrate response element binding protein. Proc. Natl. Acad. Sci. USA 2001, 98, 13710–13715.
  57. Caron, S.; Samanez, C.H.; Dehondt, H.; Ploton, M.; Briand, O.; Lien, F.; Dorchies, E.; Dumont, J.; Postic, C.; Cariou, B.; et al. Farnesoid X Receptor Inhibits the Transcriptional Activity of Carbohydrate Response Element Binding Protein in Human Hepatocytes. Mol. Cell. Biol. 2013, 33, 2202–2211.
  58. Shen, H.; Zhang, Y.; Ding, H.; Wang, X.; Chen, L.; Jiang, H.; Shen, X. Farnesoid X Receptor Induces GLUT4 Expression Through FXR Response Element in the GLUT4 Promoter. Cell. Physiol. Biochem. 2008, 22, 1–14.
  59. Seyer, P.; Vallois, D.; Poitry-Yamate, C.; Schutz, F.; Metref, S.; Tarussio, D.; Maechler, P.; Staels, B.; Lanz, B.; Grueter, R.; et al. Hepatic glucose sensing is required to preserve beta cell glucose competence. J. Clin. Investig. 2013, 123, 1662–1676.
  60. Katsuma, S.; Hirasawa, A.; Tsujimoto, G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 2005, 329, 386–390.
  61. Thomas, C.; Gioiello, A.; Noriega, L.; Strehle, A.; Oury, J.; Rizzo, G.; Macchiarulo, A.; Yamamoto, H.; Mataki, C.; Pruzanski, M.; et al. TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis. Cell Metab. 2009, 10, 167–177.
  62. Brighton, C.; Rievaj, J.; Kuhre, R.E.; Glass, L.; Schoonjans, K.; Holst, J.J.; Gribble, F.; Reimann, F. Bile Acids Trigger GLP-1 Release Predominantly by Accessing Basolaterally Located G Protein–Coupled Bile Acid Receptors. Endocrinology 2015, 156, 3961–3970.
  63. Christiansen, C.B.; Trammell, S.; Albrechtsen, N.J.W.; Schoonjans, K.; Albrechtsen, R.; Gillum, M.; Kuhre, R.E.; Holst, J.J. Bile acids drive colonic secretion of glucagon-like-peptide 1 and peptide-YY in rodents. Am. J. Physiol. Liver Physiol. 2019, 316, G574–G584.
  64. Bala, V.; Rajagopal, S.; Kumar, D.P.; Nalli, A.D.; Mahavadi, S.; Sanyal, A.J.; Grider, J.R.; Murthy, K.S. Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC-epsilon pathway and modulated by endogenous H2S. Front. Physiol. 2014, 5, 420.
  65. Muller, T.D.; Finan, B.; Bloom, S.R.; D’Alessio, D.; Drucker, D.J.; Flatt, P.R.; Fritsche, A.; Gribble, F.; Grill, H.J.; Habener, J.F.; et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 2019, 30, 72–130.
  66. Stožer, A.; Leitgeb, E.P.; Pohorec, V.; Dolenšek, J.; Bombek, L.K.; Gosak, M.; Klemen, M.S. The Role of cAMP in Beta Cell Stimulus–Secretion and Intercellular Coupling. Cells 2021, 10, 1658.
  67. Wang, X.; Zhou, J.; Doyle, M.E.; Egan, J.M. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 2001, 142, 1820–1827.
  68. Trabelsi, M.-S.; Daoudi, M.; Prawitt, J.; Ducastel, S.; Touche, V.; Sayin, S.I.; Perino, A.; Brighton, C.A.; Sebti, Y.; Kluza, J.; et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat. Commun. 2015, 6, 7629.
  69. Zheng, X.; Chen, T.; Jiang, R.; Zhao, A.; Wu, Q.; Kuang, J.; Sun, D.; Ren, Z.; Li, M.; Zhao, M.; et al. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metab. 2021, 33, 791–803.e7.
  70. Chávez-Talavera, O.; Wargny, M.; Pichelin, M.; Descat, A.; Vallez, E.; Kouach, M.; Bigot-Corbel, E.; Joliveau, M.; Goossens, J.-F.; Le May, C.; et al. Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes. Metabolism 2020, 103, 154042.
  71. Zheng, X.; Chen, T.; Zhao, A.; Ning, Z.; Kuang, J.; Wang, S.; You, Y.; Bao, Y.; Ma, X.; Yu, H.; et al. Hyocholic acid species as novel biomarkers for metabolic disorders. Nat. Commun. 2021, 12, 1487.
  72. Wang, T.Y.; Liu, M.; Portincasa, P.; Wang, D.Q.-H. New insights into the molecular mechanism of intestinal fatty acid absorption. Eur. J. Clin. Investig. 2013, 43, 1203–1223.
  73. Wang, Y.; Viscarra, J.; Kim, S.-J.; Sul, H.S. Transcriptional regulation of hepatic lipogenesis. Nat. Rev. Mol. Cell Biol. 2015, 16, 678–689.
  74. Ipsen, D.H.; Lykkesfeldt, J.; Tveden-Nyborg, P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell. Mol. Life Sci. 2018, 75, 3313–3327.
  75. Watanabe, M.; Houten, S.M.; Wang, L.; Moschetta, A.; Mangelsdorf, D.J.; Heyman, R.A.; Moore, D.D.; Auwerx, J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Investig. 2004, 113, 1408–1418.
  76. Dixon, E.; Nardo, A.; Claudel, T.; Trauner, M. The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD. Genes 2021, 12, 645.
  77. Sapiro, J.M.; Mashek, M.T.; Greenberg, A.S.; Mashek, D.G. Hepatic triacylglycerol hydrolysis regulates peroxisome proliferator-activated receptor α activity. J. Lipid Res. 2009, 50, 1621–1629.
  78. Xu, J.; Li, Y.; Chen, W.-D.; Xu, Y.; Yin, L.; Ge, X.; Jadhav, K.; Adorini, L.; Zhang, Y. Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis. Hepatology 2014, 59, 1761–1771.
  79. Wang, Y.D.; Chen, W.D.; Wang, M.; Yu, D.; Forman, B.M.; Huang, W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008, 48, 1632–1643.
  80. Calmus, Y.; Guechot, J.; Podevin, P.; Bonnefis, M.-T.; Giboudeau, J.; Poupon, R. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor–α production by monocytes. Hepatology 1992, 16, 719–723.
  81. Jung, H.; Chen, J.; Hu, X.; Sun, H.; Wu, S.-Y.; Chiang, C.-M.; Kemper, B.; Chen, L.-F.; Kemper, J.K. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination. JCI Insight 2021, 6, e141640.
  82. Kim, D.-H.; Xiao, Z.; Kwon, S.; Sun, X.; Ryerson, D.; Tkac, D.; Ma, P.; Wu, S.-Y.; Chiang, C.-M.; Zhou, E.; et al. A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity. EMBO J. 2015, 34, 184–199.
  83. Mottis, A.; Mouchiroud, L.; Auwerx, J. Emerging roles of the corepressors NCoR1 and SMRT in homeostasis. Genes Dev. 2013, 27, 819–835.
  84. Vavassori, P.; Mencarelli, A.; Renga, B.; Distrutti, E.; Fiorucci, S. The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity. J. Immunol. 2009, 183, 6251–6261.
  85. Zou, A.; Magee, N.; Deng, F.; Lehn, S.; Zhong, C.; Zhang, Y. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. J. Biol. Chem. 2018, 293, 8656–8671.
  86. Yuk, J.-M.; Shin, D.-M.; Lee, H.-M.; Kim, J.-J.; Kim, S.-W.; Jin, H.S.; Yang, C.-S.; Park, K.A.; Chanda, D.; Kim, D.-K.; et al. The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors. Nat. Immunol. 2011, 12, 742–751.
  87. Cao, S.; Meng, X.; Li, Y.; Sun, L.; Jiang, L.; Xuan, H.; Chen, X. Bile Acids Elevated in Chronic Periaortitis Could Activate Farnesoid-X-Receptor to Suppress IL-6 Production by Macrophages. Front. Immunol. 2021, 12, 632864.
  88. Pols, T.W.; Nomura, M.; Harach, T.; Sasso, G.L.; Oosterveer, M.H.; Thomas, C.; Rizzo, G.; Gioiello, A.; Adorini, L.; Pellicciari, R.; et al. TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid Loading. Cell Metab. 2011, 14, 747–757.
  89. Boutilier, A.; Elsawa, S. Macrophage Polarization States in the Tumor Microenvironment. Int. J. Mol. Sci. 2021, 22, 6995.
  90. Shi, Y.; Su, W.; Zhang, L.; Shi, C.; Zhou, J.; Wang, P.; Wang, H.; Shi, X.; Wei, S.; Wang, Q.; et al. TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation. Front. Immunol. 2021, 11, 609060.
  91. Biagioli, M.; Carino, A.; Cipriani, S.; Francisci, D.; Marchiano, S.; Scarpelli, P.; Sorcini, D.; Zampella, A.; Fiorucci, S. The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis. J. Immunol. 2017, 199, 718–733.
  92. Hu, J.; Wang, C.; Huang, X.; Yi, S.; Pan, S.; Zhang, Y.; Yuan, G.; Cao, Q.; Ye, X.; Li, H. Gut microbiota-mediated secondary bile acids regulate dendritic cells to attenuate autoimmune uveitis through TGR5 signaling. Cell Rep. 2021, 36, 109726.
  93. Hang, S.; Paik, D.; Yao, L.; Kim, E.; Trinath, J.; Lu, J.; Ha, S.; Nelson, B.N.; Kelly, S.P.; Wu, L.; et al. Bile acid metabolites control TH17 and Treg cell differentiation. Nature 2019, 576, 143–148.
  94. Zhang, W.; Liu, X.; Zhu, Y.; Liu, X.; Gu, Y.; Dai, X.; Li, B. Transcriptional and posttranslational regulation of Th17/Treg balance in health and disease. Eur. J. Immunol. 2021, 51, 2137–2150.
  95. Sato, Y.; Atarashi, K.; Plichta, D.R.; Arai, Y.; Sasajima, S.; Kearney, S.M.; Suda, W.; Takeshita, K.; Sasaki, T.; Okamoto, S.; et al. Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians. Nat. Cell Biol. 2021, 599, 458–464.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Academic Video Service
Feedback